These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 35135136)

  • 1. Precision Trial Drawer, a Computational Tool to Assist Planning of Genomics-Driven Trials in Oncology.
    Melloni GEM; Guida A; Curigliano G; Botteri E; Esposito A; Kamal M; Le Tourneau C; Riva L; Magi A; de Maria R; Pelicci P; Mazzarella L
    JCO Precis Oncol; 2018 Nov; 2():1-16. PubMed ID: 35135136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial.
    Belin L; Kamal M; Mauborgne C; Plancher C; Mulot F; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Ricci F; Alt M; Loirat D; Sablin MP; Paoletti X; Servois V; Le Tourneau C
    Ann Oncol; 2017 Mar; 28(3):590-596. PubMed ID: 27993804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The project data sphere initiative: accelerating cancer research by sharing data.
    Green AK; Reeder-Hayes KE; Corty RW; Basch E; Milowsky MI; Dusetzina SB; Bennett AV; Wood WA
    Oncologist; 2015 May; 20(5):464-e20. PubMed ID: 25876994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial.
    Le Tourneau C; Kamal M; Trédan O; Delord JP; Campone M; Goncalves A; Isambert N; Conroy T; Gentien D; Vincent-Salomon A; Pouliquen AL; Servant N; Stern MH; Le Corroller AG; Armanet S; Rio Frio T; Paoletti X
    Target Oncol; 2012 Dec; 7(4):253-65. PubMed ID: 23161020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials.
    Meric-Bernstam F; Brusco L; Shaw K; Horombe C; Kopetz S; Davies MA; Routbort M; Piha-Paul SA; Janku F; Ueno N; Hong D; De Groot J; Ravi V; Li Y; Luthra R; Patel K; Broaddus R; Mendelsohn J; Mills GB
    J Clin Oncol; 2015 Sep; 33(25):2753-62. PubMed ID: 26014291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementing a comprehensive translational oncology platform: from molecular testing to actionability.
    Mitri ZI; Parmar S; Johnson B; Kolodzie A; Keck JM; Morris M; Guimaraes AR; Beckett BR; Borate U; Lopez CD; Kemmer KA; Alumkal JJ; Beer TM; Corless CL; Mills GB; Gray JW; Bergan RC
    J Transl Med; 2018 Dec; 16(1):358. PubMed ID: 30551737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design.
    Flaherty KT; Gray R; Chen A; Li S; Patton D; Hamilton SR; Williams PM; Mitchell EP; Iafrate AJ; Sklar J; Harris LN; McShane LM; Rubinstein LV; Sims DJ; Routbort M; Coffey B; Fu T; Zwiebel JA; Little RF; Marinucci D; Catalano R; Magnan R; Kibbe W; Weil C; Tricoli JV; Alexander B; Kumar S; Schwartz GK; Meric-Bernstam F; Lih CJ; McCaskill-Stevens W; Caimi P; Takebe N; Datta V; Arteaga CL; Abrams JS; Comis R; O'Dwyer PJ; Conley BA;
    J Natl Cancer Inst; 2020 Oct; 112(10):1021-1029. PubMed ID: 31922567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarker-Driven Oncology Clinical Trials: Novel Designs in the Era of Precision Medicine.
    Moore DC; Guinigundo AS
    J Adv Pract Oncol; 2023 Apr; 14(Suppl 1):9-13. PubMed ID: 37206904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An overview of precision oncology basket and umbrella trials for clinicians.
    Park JJH; Hsu G; Siden EG; Thorlund K; Mills EJ
    CA Cancer J Clin; 2020 Mar; 70(2):125-137. PubMed ID: 32031692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioinformatics for precision medicine in oncology: principles and application to the SHIVA clinical trial.
    Servant N; Roméjon J; Gestraud P; La Rosa P; Lucotte G; Lair S; Bernard V; Zeitouni B; Coffin F; Jules-Clément G; Yvon F; Lermine A; Poullet P; Liva S; Pook S; Popova T; Barette C; Prud'homme F; Dick JG; Kamal M; Le Tourneau C; Barillot E; Hupé P
    Front Genet; 2014; 5():152. PubMed ID: 24910641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards.
    Perera-Bel J; Hutter B; Heining C; Bleckmann A; Fröhlich M; Fröhling S; Glimm H; Brors B; Beißbarth T
    Genome Med; 2018 Mar; 10(1):18. PubMed ID: 29544535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH.
    Coyne GO; Takebe N; Chen AP
    Curr Probl Cancer; 2017; 41(3):182-193. PubMed ID: 28372823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A web application for the design of multi-arm clinical trials.
    Grayling MJ; Wason JM
    BMC Cancer; 2020 Jan; 20(1):80. PubMed ID: 32005187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Landscape of Pediatric Precision Oncology: Program Design, Actionable Alterations, and Clinical Trial Development.
    Langenberg KPS; Looze EJ; Molenaar JJ
    Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges, opportunities, and innovative statistical designs for precision oncology trials.
    Yin J; Shen S; Shi Q
    Ann Transl Med; 2022 Sep; 10(18):1038. PubMed ID: 36267789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice.
    Vasan N; Yelensky R; Wang K; Moulder S; Dzimitrowicz H; Avritscher R; Wang B; Wu Y; Cronin MT; Palmer G; Symmans WF; Miller VA; Stephens P; Pusztai L
    Oncologist; 2014 May; 19(5):453-8. PubMed ID: 24710307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology.
    Janiaud P; Serghiou S; Ioannidis JPA
    Cancer Treat Rev; 2019 Feb; 73():20-30. PubMed ID: 30572165
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.